ELF4: The Potential Drug Target and Biomarker (G2000)
ELF4: The Potential Drug Target and Biomarker
ELF4, or E74-like factor 4, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer. In recent years, researchers have been investigating the potential drug targets and biomarkers for ELF4, with a focus on its role in cancer progression.
The ELF4 gene was identified in the late 1990s as a critical regulator of the cell cycle in Drosa anomala, a type of fruit fly that is commonly used in research studies. The gene encodes a protein that is highly conserved across various species and has been shown to play a critical role in the regulation of cell growth, DNA replication, and apoptosis.
ELF4 has been shown to be involved in a number of cellular processes that are important for cancer progression. For example, studies have shown that ELF4 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to play a role in the development and progression of cancer stem cells, which are cells that have the ability to self-replify and give rise to new cancerous tumors.
In addition to its role in cancer, ELF4 has also been implicated in a number of other diseases and disorders. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's, and has also been linked to a number of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
Despite the potential for ELF4 to be a drug target, much research is still needed to fully understand its role in these diseases and to determine the best way to target it. However, there are several approaches that researchers are exploring to identify potential drug candidates for ELF4.
One approach is to use libraries of small molecules to identify compounds that can interact with ELF4 and inhibit its activity. This approach has already led to the identification of several potential drug candidates, including inhibitors of the protein's functions as a negative regulator of the cell cycle.
Another approach is to use ELF4-targeted antibodies to study its behavior in live cells. This has led to the development of techniques for using advanced imaging techniques, such as live-cell imaging, to study ELF4's localization and interactions with other cellular components.
While more research is needed to fully understand the role of ELF4 in disease, it is clear that it has the potential to be a valuable drug target and biomarker. As research continues to progress, it is likely that new insights will emerge and new drug candidates will be identified.
Protein Name: E74 Like ETS Transcription Factor 4
Functions: Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the hematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter (By similarity). Transactivates the PRF1 promoter in natural killer (NK) cells and CD8+ T cells (PubMed:34326534). Plays a role in the development and function of NK and NK T-cells and in innate immunity. Controls the proliferation and homing of CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2 (By similarity). Controls cell senescence in a p53-dependent manner. Can also promote cellular transformation through inhibition of the p16 pathway. Is a transcriptional regulator of inflammation, controlling T-helper 17 (Th17) cells and macrophage inflammatory responses. Required for sustained transcription of anti-inflammatory genes, including IL1RN (PubMed:34326534, PubMed:35266071). Is a negative regulator of pro-inflammatory cytokines expression including IL17A, IL1B, IL6, TNFA and CXCL1 (PubMed:34326534, PubMed:35266071). Down-regulates expression of TREM1, a cell surface receptor involved in the amplification of inflammatory responses (By similarity) (PubMed:34326534, PubMed:35266071)
The "ELF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELF4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV
